Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 8/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12822424 | 0.91 | TUBB1 (0.44) | TUBB1ALOX5APFEN1NAAA | |
| SCHEMBL12739415 | 0.88 | TUBB1 (0.46) | TUBB1NFE2L2PTGS1ALOX5APFEN1 | |
| SCHEMBL12739402 | 0.88 | TUBB1 (0.46) | TUBB1NFE2L2PTGS1PTGS2 | |
| SCHEMBL12716435 | 0.87 | NFE2L2 (0.35) | TUBB1NFE2L2PTGS1ALOX5APFEN1 | |
| SCHEMBL12822086 | 0.87 | NFE2L2 (0.35) | TUBB1NFE2L2PTGS1ALOX5APFEN1 | |
| SCHEMBL13586344 | 0.85 | ALOX5AP (0.32) | TUBB1ALOX5APFEN1 | |
| SCHEMBL12821230 | 0.84 | TUBB1 (0.41) | TUBB1NFE2L2NAAA | |
| SCHEMBL12822707 | 0.84 | TUBB1 (0.48) | TUBB1NFE2L2PTGS1 | |
| SCHEMBL12739405 | 0.83 | TUBB1 (0.42) | TUBB1NFE2L2PTGS1 | |
| SCHEMBL12823732 | 0.83 | NAAA (0.41) | ALOX5APFEN1NAAAPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| WO-2009150966-A1 | TETRACYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | TUBB1 664/4885NFE2L2 1574/4885PTGS1 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.